Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Dr Maycock described that the Department of Health had been advised that the NBTS should reach the position of being able to supply the amount of concentrate from 275,000 donations by 1975, but this was clearly not possible.

  • Read more about Dr Maycock described that the Department of Health had been advised that the NBTS should reach the position of being able to supply the amount of concentrate from 275,000 donations by 1975, but this was clearly not possible.

The goal of 275,000 donations for Factor 8 production had not been met a year after it had been given.

  • Read more about The goal of 275,000 donations for Factor 8 production had not been met a year after it had been given.

Dr Maycock recognised a need for blood transfusion services to be "self-supporting".

  • Read more about Dr Maycock recognised a need for blood transfusion services to be "self-supporting".

Dr Biggs maintained that concentrates were the optimum treatment; that commercial product was available but, despite that, UK domestic production should increase; and that home treatment was desirable as a goal.

  • Read more about Dr Biggs maintained that concentrates were the optimum treatment; that commercial product was available but, despite that, UK domestic production should increase; and that home treatment was desirable as a goal.

Professor Dame Marcela Contreras described that the routine recovery of plasma from whole blood donations, especially increased by the separation of red blood cells and the use of SAG-M plasma, were still thought to be the methods of choice, with plasmapheresis making up for the deficit.

  • Read more about Professor Dame Marcela Contreras described that the routine recovery of plasma from whole blood donations, especially increased by the separation of red blood cells and the use of SAG-M plasma, were still thought to be the methods of choice, with plasmapheresis making up for the deficit.

Plasmapheresis first began in the United Kingdom.

  • Read more about Plasmapheresis first began in the United Kingdom.

Lord Owen described that there was no "reason for anybody who was involved in the Department during that period to hang their head in shame" about steps taken to achieve self-sufficiency.

  • Read more about Lord Owen described that there was no "reason for anybody who was involved in the Department during that period to hang their head in shame" about steps taken to achieve self-sufficiency.

The UK was self-sufficient in meeting Factor 9 needs, and remained so until products sourced from British donor plasma ceased being used because of the threat of vCJD.

  • Read more about The UK was self-sufficient in meeting Factor 9 needs, and remained so until products sourced from British donor plasma ceased being used because of the threat of vCJD.

Planning was under way for a new building to constitute BPL at Elstree. A plasma supply target of 435,000 kilograms, including this element for cryoprecipitate production, was broadly maintained with a growing consensus that demand for Factor 8 would increase in the region to around 100 million international units.

  • Read more about Planning was under way for a new building to constitute BPL at Elstree. A plasma supply target of 435,000 kilograms, including this element for cryoprecipitate production, was broadly maintained with a growing consensus that demand for Factor 8 would increase in the region to around 100 million international units.

Dr Mayne described that haemophilia patients in Northern Ireland who were treated with concentrate received limited quantities of concentrate from Elstree and Oxford.

  • Read more about Dr Mayne described that haemophilia patients in Northern Ireland who were treated with concentrate received limited quantities of concentrate from Elstree and Oxford.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 285
  • Page 286
  • Page 287
  • Page 288
  • Current page 289
  • Page 290
  • Page 291
  • Page 292
  • Page 293
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.